Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 25, 2015 2:38 PM ET


Company Overview of Warp Drive Bio, LLC

Company Overview

Warp Drive Bio, LLC develops genomic technology to discover drugs of natural origin. The company also engages in development of drugs. Warp Drive Bio, LLC was incorporated in 2010 and is based in Cambridge, Massachusetts.

215 First Street

Cambridge, MA 02142

United States

Founded in 2010





Key Executives for Warp Drive Bio, LLC

Chief Executive Officer
Age: 50
Co-Founder, Chairman of The Scientific Advisory Board, President, Chief Scientific Officer and Director
Age: 55
Founder and Executive Chairman
Age: 42
Chief Operating Officer
Compensation as of Fiscal Year 2014.

Warp Drive Bio, LLC Key Developments

Warp Drive Bio Announces Executive Changes

Warp Drive Bio announced the appointment of Laurence Reid to chief executive officer. Dr. Reid succeeds CEO and co-founder Gregory Verdine who will continue to serve the company as president and chief scientific officer, as well as chairman of the company’s scientific advisory board. Dr. Verdine will also remain on Warp Drive Bio’s board of directors and will retain his appointment as a venture partner with Third Rock Ventures. Dr. Reid brings to Warp Drive more than 25 years of experience in the global biopharmaceutical industry, with a focus on building innovative companies. He is an entrepreneur-in-residence at Third Rock Ventures, and most recently served as the chief business officer of Alnylam Pharmaceuticals Inc.

Warp Drive Bio, LLC Presents at Life Sciences Summit 2014, Oct-28-2014 through Oct-29-2014

Warp Drive Bio, LLC Presents at Life Sciences Summit 2014, Oct-28-2014 through Oct-29-2014. Venue: 10 on the Park at Time Warner Center, 60 Columbus Circle, 10th Floor, New York, NY 10019, United States. Presentation Date & Speakers: Oct-29-2014, Gregory L. Verdine, Co-Founder and Chief Executive Officer.

Warp Drive Bio, LLC Announces Executive Changes

Warp Drive Bio announced the appointment of scientist and company co-founder Gregory Verdine, Ph.D., to chief executive officer. Dr. Verdine succeeds founding CEO Alexis Borisy, who will remain on Warp Drive Bio's board of directors and will assume the position of executive chairman. In addition, Warp Drive Bio has appointed industry veteran James Nichols, Ph.D., to the newly created role of chief operating officer, and drug hunter Julian Adams, Ph.D., to its board of directors. A biopharmaceutical executive and entrepreneur with more than 15 years of life sciences experience, Dr. Nichols joins Warp Drive Bio in the newly created role of chief operating officer. Prior to joining Warp Drive Bio, Dr. Nichols was president and chief operating officer of Resolvyx Pharmaceuticals Inc., where he advanced two programs through early clinical development, led the company's financing and business development activities and closed a strategic partnership on the company's lead clinical ophthalmic program. Prior to joining Resolvyx, Dr. Nichols was vice president of therapeutics at CombinatoRx Inc. (now Zalicus), where he led product and portfolio strategy, overseeing seven programs from discovery through Phase 2, and was instrumental in closing multiple strategic deals and financing rounds. Previously, Dr. Nichols was a management consultant at Braun Consulting, a health care focused consulting firm (acquired by Fair Isaac). He was subsequently a Helen Hay Whitney Postdoctoral at Stanford University Medical School. New board member and world-renowned scientist Dr. Adams currently serves as president, research and development at Infinity Pharmaceuticals Inc., where he is responsible for the full spectrum of Infinity's drug discovery, preclinical and clinical development strategy, and regulatory affairs activities. Prior to joining Infinity in 2003, Dr. Adams was the senior vice president, drug discovery and development at Millennium Pharmaceuticals, where he had global responsibility for multiple drug discovery programs, including the successful discovery and development of Velcade(R) (bortezomib), a proteasome inhibitor for cancer therapy. Earlier in his career, Dr. Adams served in senior positions at LeukoSite and ProScript and as director, medicinal chemistry at Boehringer Ingelheim, where he successfully discovered the drug Viramune(R) (nevirapine) for HIV.

Similar Private Companies By Industry

Company Name Region
Bristol-Myers Squibb & Gilead Sciences, LLC United States
Celera Corporation United States
Anagen Therapeutics, Inc. United States
GrayBug, Inc. United States
Life Sciences Advanced Technologies, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Warp Drive Bio, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at